Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study

• Published in: Journal of clinical oncology Vol. 11; no. 1; p. 161
• Main Authors: Bukowski, R M, Wolfe, M, Levine, H S, Crawford, D E, Stephens, R L, Gaynor, E, Harker, W G
• Format: Journal Article
• Language: English
• Published: United States 01.01.1993
• Subjects: Adolescent; Adrenal Cortex Neoplasms - drug therapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carcinoma - drug therapy; Carcinoma - secondary; Cisplatin - administration & dosage; Female; Humans; Male; Middle Aged; Mitotane - administration & dosage
• ISSN: 0732-183X
• DOI: 10.1200/JCO.1993.11.1.161

Previous reports of chemotherapy in patients with adrenal cancer have described responses to cisplatin (CDDP). Because of these reports of good results, a phase II trial that used CDDP with and without mitotane (o,p'DDD) was initiated. Patients with metastatic or residual adrenocortical carcinoma with objectively measurable disease or biochemical abnormalities were divided into good-risk and poor-risk categories. The latter received CDDP 100 mg/m2 intravenously, and the former received 75 mg/m2. o,p'DDD was administered at a 1,000-mg dose orally four times a day along with cortisone acetate and Florinef (fludrocortisone acetate; Bristol-Myers Squibb Co, Princeton, NJ). Of a total of 42 patients entered onto the study, 37 were eligible. Twenty-nine patients received good-risk and eight received poor-risk doses of CDDP. Functioning tumors were present in 45% of patients. Objective responses were noted in 30% (11 of 37) patients (95% confidence interval, 16% to 50%). Response duration was 7.9 months, and the median time to response was 76 days. The median survival of the 37 eligible patients was 11.8 months, and a significant survival advantage was found for patients who underwent prior surgical removal of their primary tumor or bulky disease, who had a performance status of 0 or 1, or who had synchronous metastatic disease. Toxicity of the CDDP and o,p'DDD combination was moderate to severe, and the most common side effects were gastrointestinal, renal, and neurologic. The regimen of CDDP and o,p'DDD has activity in patients with adrenocortical carcinoma; however, the toxicity of this treatment was moderate to severe.